Prices delayed by 15 minutes
Next earnings report: 03 November 2026, before market open · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Pfizer, Inc. trades on NYSE under the ticker PFE. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks PFE has traded between 23.62 $ and 29.21 $. As of 09 October 2026 the price stood 75.13 % of the way from the 52-week low to the high.
Over one year PFE shares rose 5.90 %; over six months they rose 2.20 %. Volatility over 90 days is 20.55 %. Dividends are not included: this is price change only, as of 09 October 2026.
PFE trades at a price-to-earnings ratio of 21.1, below the sector median of 24.8. Price to sales is 2.5, below the sector median of 3.9. Price to book is 1.8, below the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 27.90 | 28.00 | 27.48 | 27.82 | 44M |
| 07 October 2026 | 27.62 | 28.17 | 27.55 | 28.00 | 31M |
| 06 October 2026 | 27.48 | 27.71 | 27.20 | 27.50 | 24M |
| 05 October 2026 | 27.65 | 27.72 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Pfizer is a drug maker working through the decline after its pandemic peak and rebuilding its portfolio by acquisition.
The pandemic gave the company an exceptionally large but temporary revenue source — a vaccine and an antiviral. Their sales fell sharply, and for several years afterwards year-on-year comparisons looked disastrous because of the high base rather than any deterioration in the core business.
The cash earned then went into deals: oncology through the Seagen acquisition, migraine treatments, vaccines and an obesity programme. The purpose is to replace departing revenue and prepare for patent expiries on several large medicines in the second half of the decade.
The company pays one of the highest dividends in the sector, and its sustainability is a recurring investor debate: the payout sits alongside debt raised for acquisitions. The risks are the industry's usual ones — trial results, regulatory decisions and pressure on drug pricing.
Address:66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192, US
Pfizer, Inc. reported revenue of 63.3B $ and net income of 7.5B $ over the last four quarters. Net margin is 11.83 %. Revenue changed by +1.36 % year over year. Earnings per share are 1.31 $. Market capitalisation is 158.2B $.
PFE has a return on equity of 8.31 %, above the sector median of −41.68 %. Return on assets is 3.61 %, above the sector median of −32.11 %.
| 1.2B |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| NVONovo Nordisk A/S | 38.58 | +1.03 % | 545M |
| 27.12 |
| 27.41 |
| 33M |
| 02 October 2026 | 28.15 | 28.16 | 27.44 | 27.80 | 35M |
| 01 October 2026 | 28.45 | 28.59 | 28.08 | 28.12 | 30M |
| 30 September 2026 | 28.79 | 28.95 | 28.52 | 28.52 | 34M |
| 29 September 2026 | 28.60 | 28.76 | 28.26 | 28.72 | 33M |
| 28 September 2026 | 28.62 | 28.87 | 28.39 | 28.72 | 25M |
| 25 September 2026 | 28.45 | 28.69 | 28.17 | 28.67 | 28M |
| 24 September 2026 | 28.20 | 28.85 | 28.20 | 28.41 | 35M |
| 23 September 2026 | 27.96 | 28.23 | 27.84 | 28.18 | 34M |
| 22 September 2026 | 27.74 | 28.00 | 27.49 | 27.93 | 27M |
| 21 September 2026 | 27.65 | 27.92 | 27.53 | 27.74 | 29M |
| 18 September 2026 | 27.64 | 27.66 | 27.34 | 27.66 | 76M |
| 17 September 2026 | 27.62 | 27.81 | 27.55 | 27.64 | 29M |
| 16 September 2026 | 27.64 | 27.69 | 27.36 | 27.46 | 26M |
| 15 September 2026 | 27.62 | 27.66 | 27.25 | 27.55 | 40M |
| 14 September 2026 | 28.08 | 28.19 | 27.69 | 27.72 | 29M |
| 11 September 2026 | 27.80 | 27.85 | 27.42 | 27.72 | 26M |